GlaxoSmithKline Pharmaceuticals inches up on launching Trelegy Ellipta for COPD patients
Glaxosmithkline Pharmaceuticals is currently trading at Rs. 1593.65, up by 2.80 points or 0.18% from its previous closing of Rs. 1590.85 on the BSE.
The scrip opened at Rs. 1588.65 and has touched a high and low of Rs. 1602.05 and Rs. 1580.80 respectively. So far 1034 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1917.00 on 13-Dec-2021 and a 52 week low of Rs. 1427.95 on 30-Apr-2021.
Last one week high and low of the scrip stood at Rs. 1671.05 and Rs. 1574.95 respectively. The current market cap of the company is Rs. 27056.68 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 12.91% and 12.09% respectively.
GlaxoSmithKline Pharmaceuticals has launched Trelegy Ellipta for Chronic Obstructive Pulmonary Disease (COPD) patients. Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is the first once daily single-inhaler triple therapy (SITT) in India for COPD patients.
The product launch comes after the Drugs Controller General of India (DCGI) approved the use of Trelegy Ellipta as maintenance treatment to prevent and relieve symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) in patients aged 18 and above.
GlaxoSmithKline Pharmaceuticals is an Indian subsidiary of GlaxoSmithKline plc. The company business has a broad portfolio of innovative and established medicines, with leadership positions in respiratory and HIV.
